A new sirolimus-eluting bioresorbable scaffold with far thinner struts resulted non inferior to the Xience as to the end point of angiographic in-segment late loss (LL) powered for noninferiority testing. Even though this is a small study with angiographic end points, it might be the first step towards the return of bioresorbable scaffolds. Read also:...
EuroPCR 2021 | CLASP: 2 Year Outcomes of the New Mitral Valve Repair System
The 2-year outcomes of the transcatheter mitral valve repair system PASCAL have shown high survival and low rehospitalization rates, and durable reduction of mitral valve regurgitation. These results were provided by the CLASP trial, presented during the EuroPCR scientific sessions and simultaneously published in JACC: Cardiovascular Interventions. The PASCAL system (Edwards) has been authorized for...
ACC 2021 | HOST-EXAM: Clopidogrel vs ASA monotherapy post DAPT in PCI patients
Clopidogrel monotherapy after dual antiplatelet therapy (DAPT) was associated with reduced mortality, MI, stroke, and other events in patients receiving PCI compared against aspirin monotherapy (ASA). This information was provided by the Korean HOST-EXAM study, presented at ACC 2021 scientific sessions, and simultaneously published in the Lancet. Researchers followed patients for 2 years and observed...
ACC 2021 | ATLANTIS 4D-CT: Apixaban and Sub-Clinical Thrombosis After TAVR
Indicating apixaban after transcatheter aortic valve replacement (TAVR) does not significantly reduce the risk of sub-clinical leaflet thrombosis compared with the standard of care. These data come from the computerized tomography (CT) scan sub-study from ATLANTIS, presented during the scientific sessions of the American College of Cardiology (ACC) 2021 Congress. In patients with no prior...
ACC 2021 | ATLANTIS: Apixaban After TAVR vs. Standard of Care
Adding apixaban to the treatment of patients undergoing transcatheter aortic valve replacement (TAVR) was non-superior to standard antithrombotic treatment, according to the randomized ATLANTIS trial presented today at the American College of Cardiology (ACC) 2021 Congress. Given its easy indication and good safety profile, it could be an option to vitamin K antagonists for patients with...
ACC 2021 | TALOS-AMI: De-escalating from Ticagrelor to Clopidogrel after One Month
After one-month dual antiplatelet therapy (DAPT) with aspirin and ticagrelor, a net clinical benefit was observed when de-escalating to clopidogrel in acute myocardial infarction (AMI) patients treated with PCI. We have discussed the pros and cons of de-escalating from a potent antiplatelets Such as ticagrelor to clopidogrel since the TOPIC presented at EuroPCR in 2017. What...
The most read scientific articles on interventional cardiology of april
01- Post MI Betablockers for Good? Patients receiving optimal medical treatment after MI do not seem to benefit from betablockers in the long term, provided they do not present cardiac failure or systolic function deterioration. Read more HERE 02- Thrombocytopenia and Thrombosis May Be Linked to AstraZeneca Vaccine, Analysis Reports This is one of the...
Diagnosis and Treatment of Vaccine-Induced Thrombosis
Cerebral venous sinus thrombosis is an extremely rare manifestation of cerebrovascular disease. In the last few days, this pathology has sadly gained fame due to its association with two vector-based vaccines against SARR COV19. These are Ad26.COV2.S (Johnson & Johnson) and ChAdOx1 nCoV-19 (AstraZeneca). There have not been any reports of thrombosis or thrombocytopenia from...
Back to Basics: Ticagrelor Questioned and Clopidogrel in the Limelight
Yet another observational study has come to question the antiaggregation power of ticagrelor when it comes to death or MI reduction, pointing at its higher risk of bleeding vs. clopidogrel. This new analysis recently published in JAHA includes a large number of patients undergoing acute coronary syndrome (ACS) in the clinical practice. Ticagrelor has been...
Xience Receives CE Mark for Short and Ultrashort DAPT Schemes
Dual antiplatelet therapy (DAPT) one month after angioplasty with Xience stent was approved in Europe for patients with high risk of bleeding. The CE Mark approval comes after studies Xience 28 and Xience 90 are published. Immediately after authorization, Abbot was fast to announce what they consider to be the shortest approved scheme with the most...